Genetic diversity of vaccine candidate antigens that block Pvs25 and Pvs28 transmission in Plasmodium vivax isolates from China | BMC Infectious Diseases
World Health Organization: World malaria report 2021. 2021.
Tsuboi T, Tachibana M, Kaneko O, Torii M. Transmission-blocking vaccine for vivax malaria. Parasitol Int. 2003;52(1):1–11.
Academic google
Sauerwein RW. Vaccines that block malaria transmission: the advantage of effective malaria control. Microbes infect. 2007;9(6):792–5.
Kaslow DC. Vaccines that block transmission. immunol chem. 2002;80:287–307.
Wu Y, Sinden RE, Churcher TS, Tsuboi T, Yusibov V. Development of vaccines that block malaria transmission: from concept to product. Adv Parasitol. 2015;89:109–52.
Academic google
Grotendorst CA, Kumar N, Carter R, Kaushal DC. Surface protein expressed during transformation of zygotes from Plasmodium gallinaceum it is a target of antibodies that block transmission. Infection Immunity 1984;45(3):775–7.
Kaslow DC. Transmission-blocking vaccines: uses and current state of development. Int J Parasitol. 1997;27(2):183–9.
Kumar N, Carter R. Two-step biosynthesis of specific membrane proteins during the transformation of Plasmodium gallinaceum zygotes into ookinetes. Mol Biochem Parasitol. 1985;14(2):127–39.
Hisaeda H, Stowers AW, Tsuboi T, Collins WE, Sattabongkot JS, Suwanabun N, Torii M, Kaslow DC. Antibodies against malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infection Immunity 2000;68(12):6618–23.
Sattabongkot J, Tsuboi T, Hisaeda H, Tachibana M, Suwanabun N, Rungruang T, Cao YM, Stowers AW, Sirichaisinthop J, Coleman RE, et al. Blocking of transmission to mosquitoes by antibodies against Plasmodium vivax Pvs25 and Pvs28 malaria vaccine candidates despite antigenic polymorphism in field isolates. Am J Trop Med Hyg. 2003;69(5):536–41.
Tsuboi T, Kaslow DC, Gozar MM, Tachibana M, Cao YM, Torii M. Sequence polymorphism in two novels Plasmodium vivax ookinet surface proteins, Pvs25 and Pvs28, which are vaccine candidates that block malaria transmission. Mol Med. 1998;4(12):772–82.
Gonzalez-Ceron L, Alvarado-Delgado A, Martinez-Barnetche J, Rodriguez MH, Ovilla-Munoz M, Perez F, Hernandez-Avila JE, Sandoval MA, Rodriguez Mdel C, Villarreal-Treviño C. Surface protein sequence variation of ookinete Pvs25 and Pvs28 of Plasmodium vivax Isolates from southern Mexico and their association with local anopheline infectivity. Infect Gene Evol. 2010;10(5):645–54.
Academic google
Zakeri S, Razavi S, Djadid ND. Genetic diversity of the transmission blocking vaccine candidate antigen (Pvs25 and Pvs28) in Plasmodium vivax clinical isolates from Iran. Act Trop. 2009;109(3):176–80.
Tsuboi T, Kaneko O, Cao YM, Tachibana M, Yoshihiro Y, Nagao T, Kanbara H, Torii M. A rapid genotyping method for vivax vaccine candidates that block transmission of malaria, Pvs25 and Pvs28. Parasitol Int. 2004;53(3):211–6.
Han ET, Lee WJ, Sattabongkot J, Jang JW, Nam MH, An SS, Suh I, Lim CS. Sequence polymorphisms Plasmodium vivax Ookinete surface proteins (Pvs25 and Pvs28) from clinical isolates in Korea. Trop Med Int Health. 2010;15(9):1072–6.
Kang JM, Ju HL, Moon SU, Cho PY, Bahk YY, Sohn WM, Park YK, Cha SH, Kim TS, Na BK. Limited sequence polymorphisms of four vaccine candidate antigens that block transmission in Plasmodium vivax Korean isolates. Malar J. 2013;12:144.
Prajapati SK, Joshi H, Dua VK. antigenic repertoire of Plasmodium vivax Candidate vaccines that block transmission from the Indian subcontinent. Malar J. 2011;10:111.
Academic google
Lê HG, Kang JM, Jun H, Lee J, Moe M, Thái TL, Lin K, Myint MK, Yoo WG, Sohn WM, et al. Genetic diversity and natural selection of candidate antigens for Pvs25 and Pvs28 transmission-blocking vaccines in Plasmodium vivax Myanmar isolates. Act Trop. 2019;198:105104.
Academic google
Feng H, Zheng L, Zhu X, Wang G, Pan Y, Li Y, Yang Y, Lin Y, Cui L, Cao Y. Genetic diversity of candidate vaccines that block Pvs25 and Pvs28 transmission in Plasmodium vivax isolated from Yunnan province, China. Parasite vectors. 2011;4:224.
Snounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, do Rosario VE, Thaithong S, Brown KN. High sensitivity detection of human malaria parasites by using the nested polymerase chain reaction. Mol Biochem Parasitol. 1993;61(2):315–20.
Rozas J, Sánchez-DelBarrio JC, Messeguer X, Rozas R. DnaSP, Analysis of DNA polymorphisms by the coalescent method and others. Bioinformatics. 2003;19(18):2496–7.
Tajima F. Statistical method to test the hypothesis of neutral mutation by DNA polymorphism. Genetics. 1989;123(3):585–95.
Nei M, Gojobori T. Simple methods for estimating the number of synonymous and non-synonymous nucleotide substitutions. Mol Biol Evol. 1986;3(5):418–26.
Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol. 2013;30(12):2725–9.
Escalante AA, Cornejo OE, Freeland DE, Poe AC, Durrego E, Collins WE, Lal AA. The Monkey’s Tale: The Origin of Plasmodium vivax as a human malaria parasite. Proc Natl Acad Sci USA. 2005;102(6):1980–5.
Breman JG. Hippopotamus ears: manifestations, determinants, and estimates of malaria burden. Am J Trop Med Hyg. 2001;64(1–2 Suppl):1–11.
Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, Long CA, Lambert L, Miles AP, Wang J, et al. Pvs25H Phase 1 Vaccine Trial: A Vaccine That Blocks Transmission To Plasmodium vivax malaria. Vaccine. 2005;23(24):3131–8.
Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, et al. Phase 1 trial of Pfs25 and Pvs25 candidate vaccines to block malaria transmission formulated with montanide ISA 51. PLoS ONE. 2008;3(7):e2636.
Academic google
Saul A, Hensmann M, Sattabongkot J, Collins WE, Barnwell JW, Langermans JA, Wu Y, Long CA, Dubovsky F, Thomas AW. Immunogenicity in rhesus of the Plasmodium vivax Pvs25H mosquito stage antigen with Alhydrogel and Montanide ISA 720. Parasite Immunol. 2007;29(10):525–33.
Barry AE, Schultz L, Buckee CO, Reeder JC. Contrasting population structures of the genes encoding ten lead vaccine candidate antigens of the human malaria parasite, Plasmodium falciparum. Plus one. 2009;4(12):e8497.
Academic google
Escalante AA, Lal AA, Ayala FJ. Genetic polymorphism and natural selection in the malaria parasite Plasmodium falciparum. Genetics. 1998;149(1):189–202.
Cole-Tobian J, King CL. diversity and natural selection in Plasmodium vivax Duffy junction protein gene. Mol Biochem Parasitol. 2003;127(2):121–32.
Putaporntip C, Jongwutiwes S, Sakihama N, Ferreira MU, Kho WG, Kaneko A, Kanbara H, Hattori T, Tanabe K. Mosaic organization and heterogeneity in allelic recombination frequency of Plasmodium vivax merozoite surface protein-1 locus. Proc Natl Acad Sci USA. 2002;99(25):16348–53.
Saxena AK, Singh K, Su HP, Klein MM, Stowers AW, Saul AJ, Long CA, Garboczi DN. The essential proteins P25 and P28 of the Plasmodium mosquito stage form mosaic-like triangular prisms. Nat Struct Mol Biol. 2006;13(1):90–1.